They just neatly illustrate that many analysts are overpaid researchers,who often misinterpret their own research,although I appreciate that some may have a vested interest. Their clients will have lost large amounts of money by either- -selling short -selling existing holdings -not buying Their loss !
Finally understand their forecasts as when they say sell at 3.45 and 4.86 respectively they really mean buy as SP has jumped recently despite their stupid forecasts. What planet are they on or have they got an agends to get the price down for a potential bidder? strange people in these 2 firms.
Specialist healthcare company BTG and its partner SciClone Pharmaceuticals have received approval from the China Food and Drug Administration for the registration of DC Bead for the embolisation of a type of malignant liver tumour.
Back up to where it belongs and with all this takeover / merger activity in this sector it would be small change for a GSK/Pfizer to snap up BTG. SP of over £7 on the way and probably higher if bid comes in.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.